이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Xencor 배당금

배당금 기준 확인 0/6

Xencor 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

n/a

지급 비율

업계 평균 수익률	2.8%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
주당 순이익	-US$2.16
3년 후 배당 수익률 예측	0%

최근 배당금 업데이트

업데이트 없음

Recent updates

Lacklustre Performance Is Driving Xencor, Inc.'s (NASDAQ:XNCR) Low P/S

Jun 16

Is Xencor (NASDAQ:XNCR) Weighed On By Its Debt Load?

Mar 27

There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 29% Share Price Rise

Feb 27

Party Time: Brokers Just Made Major Increases To Their Xencor, Inc. (NASDAQ:XNCR) Earnings Forecasts

Aug 08

Xencor, Inc.'s (NASDAQ:XNCR) Shares May Have Run Too Fast Too Soon

Aug 12

Xencor GAAP EPS of -$0.57 misses by $0.10, revenue of $30.18M misses by $3.83M

Aug 03

Xencor: Capital-Efficient Platform Tech Play With A Lot Going On

Jun 03

Xencor, Inc. (NASDAQ:XNCR) Shares Could Be 35% Above Their Intrinsic Value Estimate

Feb 18

Upgrade: Analysts Just Made A Huge Increase To Their Xencor, Inc. (NASDAQ:XNCR) Forecasts

Aug 06

It's Unlikely That The CEO Of Xencor, Inc. (NASDAQ:XNCR) Will See A Huge Pay Rise This Year

Jun 20

Party Time: Brokers Just Made Major Increases To Their Xencor, Inc. (NASDAQ:XNCR) Earnings Forecasts

Apr 02

Don't Ignore The Fact That This Insider Just Sold Some Shares In Xencor, Inc. (NASDAQ:XNCR)

Mar 06

Time To Worry? Analysts Are Downgrading Their Xencor, Inc. (NASDAQ:XNCR) Outlook

Mar 02

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 XNCR 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: XNCR 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

Xencor 시장 대비 배당 수익률

XNCR 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (XNCR)	n/a
시장 하위 25% (US)	1.5%
시장 상위 25% (US)	4.7%
업계 평균 (Biotechs)	2.8%
3년 후 애널리스트 예측 (XNCR)	0%

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 XNCR 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 XNCR 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 XNCR 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: XNCR 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

Xencor 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

Lacklustre Performance Is Driving Xencor, Inc.'s (NASDAQ:XNCR) Low P/S

Consensus revenue estimates fall by 18%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Shareholder dilution

Xencor Appoints Bart Cornelissen as Senior Vice President

Is Xencor (NASDAQ:XNCR) Weighed On By Its Debt Load?

Co-Founder recently sold US$294k worth of stock

Co-Founder notifies of intention to sell stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 29% Share Price Rise

Xencor, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Insider notifies of intention to sell stock

Xencor: Standing Out With XmAb Technology

Xencor, Inc.'s (NASDAQ:XNCR) Business And Shares Still Trailing The Industry

Xencor, Inc. Appoints Dane Leone as Senior Vice President, Corporate Strategy

Co-Founder notifies of intention to sell stock

Consensus EPS estimates upgraded to US$1.66 loss

Consensus revenue estimates increase by 52%

Xencor, Inc. (NASDAQ:XNCR) Analysts Just Cut Their EPS Forecasts Substantially

Companies Like Xencor (NASDAQ:XNCR) Are In A Position To Invest In Growth

Price target decreased by 7.0% to US$40.50

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xencor, Inc. to Report Q3, 2023 Results on Nov 07, 2023

John J. Kuch to Retire as Chief Financial Officer of Xencor, Inc. in March 2024

Xencor, Inc. Appoints Barbara J. Klencke to Board of Directors

Consensus revenue estimates increase by 19%

Party Time: Brokers Just Made Major Increases To Their Xencor, Inc. (NASDAQ:XNCR) Earnings Forecasts

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xencor, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Co-Founder notifies of intention to sell stock

Xencor, Inc. Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress

Consensus EPS estimates fall by 20%

Insufficient new directors

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Co-Founder recently sold US$183k worth of stock

Consensus revenue estimates decrease by 13%

Full year 2022 earnings: EPS exceeds analyst expectations

Xencor, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Investor sentiment improves as stock rises 15%

Senior VP & Chief Medical Officer recently sold US$101k worth of stock

Senior VP & Chief Medical Officer notifies of intention to sell stock

Xencor, Inc. Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma At the American Society of Hematology Annual Meeting

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study

Xencor, Inc. to Report Q3, 2022 Results on Nov 07, 2022

High number of new directors

Xencor, Inc. to Present Seven Posters on Multiple Clinical Trials and Research-Stage Programs At the SITC Annual Meeting

High number of new directors

Xencbor, Inc. Announces the Appointment of Nancy Valente to Its Board of Directors

Xencor, Inc.'s (NASDAQ:XNCR) Shares May Have Run Too Fast Too Soon

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Xencor GAAP EPS of -$0.57 misses by $0.10, revenue of $30.18M misses by $3.83M

Xencor, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Investor sentiment improved over the past week

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell 2000 Growth-Defensive Index

Investor sentiment improved over the past week

Xencor: Capital-Efficient Platform Tech Play With A Lot Going On

Xencor, Inc. Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors

Price target decreased to US$50.13

Consensus revenue estimates increase by 40%

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Co-Founder recently sold US$72k worth of stock

Co-Founder notifies of intention to sell stock

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Xencor, Inc. (NASDAQ:XNCR) Shares Could Be 35% Above Their Intrinsic Value Estimate

Xencor, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Consensus EPS estimates increase by 52%

Consensus EPS estimates increase by 32%

Senior VP & Chief Medical Officer notifies of intention to sell stock

Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting

Zenas BioPharma Limited acquired Exclusive worldwide rights to Obexelimab from Xencor, Inc. (NasdaqGM:XNCR).

Third quarter 2021 earnings released: US$0.69 loss per share (vs US$0.22 loss in 3Q 2020)

Director Yujiro Hata has joined 3rd company board

Second quarter 2021 earnings released: EPS US$0.90 (vs US$0.61 loss in 2Q 2020)